Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma

被引：0
|
作者：
McKean, Meredith
Aggen, David Henry
Lakhani, Nehal J.
Bashir, Babar
Luke, Jason J.
Hoffman-Censits, Jean H.
Alhalabi, Omar
Bowman, Isaac Alex
Guancial, Elizabeth A.
Tan, Alan
Lingaraj, Trupti
Timothy, Marissa
Kacena, Katherine
Malek, Karim S.
Santillana, Sergio
机构：
[1] Sarah Cannon Res Inst, Tennessee Oncol, PLLC, Nashville, TN USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] START Midwest, Grand Rapids, MI USA
[4] Thomas Jefferson Univ, Sarah Cannon Res Inst, Philadelphia, PA USA
[5] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA USA
[6] Univ Pittsburgh, Pittsburgh, PA USA
[7] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[10] Florida Canc Specialists, Sarasota, FL USA
[11] Rush Univ, Med Ctr, Chicago, IL USA
[12] Ikena Oncol, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3169
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors
    Tolcher, Anthony W.
    Wu, Xiaohua
    Zhang, Jian
    Barve, Minal A.
    Gabrail, Nashat Y.
    Sommerhalder, David
    Rivera, Ildefonso I. Rodriguez
    Wilks, Sharon
    Wu, Yong
    Liu, Rujiao
    Gao, Shuiping
    Valiyil, Akhilkrishna
    Sayi, Ntombizodwa
    Germa, Caroline
    Qi, Charlie
    Chen, Lei
    Yu, Steven
    Yao, Jenny
    Zhu, Xuelian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations.
    Janku, Filip
    Kauh, John S.
    Tucci, Christopher
    Yang, Zhao
    Kania, Marek K.
    Alese, Olatunji B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study
    Thein, Kyaw Z.
    Fu, Siqing
    Janku, Filip
    Tsimberidou, Apostolia M.
    Piha-Paul, Sarina A.
    Karp, Daniel D.
    Shah, Jatin
    Milton, Denai R.
    Gong, Jing
    Sulovic, Selma
    McQuinn, Lacey
    Stephen, Bettzy A.
    Colen, Rivka R.
    Carter, Brett W.
    Meric-Bernstam, Funda
    Naing, Aung
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2022, 5 (01) : 10 - 12
  • [44] Re: Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results from a Phase 1/2 Open-Label Study Editorial Comment
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2018, 199 (05): : 1110 - 1110
  • [45] A phase I, open-label study of GSK3174998 administered alone and in combination with pembrolizumab in patients (pts) with selected advanced solid tumors (ENGAGE-1)
    Infante, Jeffrey
    Ahlers, Christoph M.
    Hodi, F. Stephen
    Postel-Vinay, Sopie
    Schellens, Jan H. M.
    Heymach, John V.
    Autio, Karen
    Barnette, Mary
    Struemper, Herbert
    Watmuff, Maura
    Paul, Elaine M.
    Kaufman, David R.
    Weber, Jeffrey S.
    Hoos, Axel
    CANCER RESEARCH, 2016, 76
  • [46] A phase I open-label study of FGFR/VEGFR inhibitor FH-2001 in patients with advanced solid tumors
    Song, Zhengbo
    Hui, Ai-min
    Wu, Zhuli
    Liu, Huilong
    Cheng, Xiangdong
    CANCER RESEARCH, 2022, 82 (12)
  • [47] Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
    Plimack, Elizabeth R.
    Bellmunt, Joaquim
    Gupta, Shilpa
    Berger, Raanan
    Chow, Laura Q. M.
    Juco, Jonathan
    Lunceford, Jared
    Saraf, Sanatan
    Perini, Rodolfo F.
    O'Donnell, Peter H.
    LANCET ONCOLOGY, 2017, 18 (02): : 212 - 220
  • [48] Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma or renal cell carcinoma
    Maia, Manuel Caitano
    Agarwal, Neeraj
    McGregor, Bradley
    Vaishampayan, Ulka
    Choueiri, Toni K.
    Green, Marjorie
    Hessel, Colin
    Scheffold, Christian
    Schwab, Gisela
    Powles, Thomas
    Pal, Sumanta
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [49] transcendIT-101: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors.
    Davar, Diwakar
    Singel, Stina M.
    Nyamuswa, Gil
    Tuan-Anh Tran
    Wu, Yang
    Grewal, Jaspreet
    Aghmesheh, Morteza
    Spira, Alexander
    Ganju, Vinod
    Rand, Jamie
    Frentzas, Sophia
    Bajor, David
    Gabrail, Nashat
    CANCER RESEARCH, 2022, 82 (12)
  • [50] IL believe: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon IL-2 ß/γ alone or in combination with pembrolizumab or standard-of-care chemotherapy in patients with locally advanced or metastatic solid tumors
    Starodub, Alexander
    Gabrail, Nashat Y.
    Zhang, Ying
    Castro, Davis Y. Torrejon
    Slavsky, Sibel
    Singel, Stina Mui
    Powderly, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345